SynthesisScientific reports2017
Risk of Pleural Recurrence in Early Stage Lung Cancer Patients after Percutaneous Transthoracic Needle Biopsy: A Meta-analysis.
Synthesis in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Balancing diagnostic approach and oncologic risk in surgically resected lung cancer: propensity-matched analysis of intraoperative versus percutaneous biopsy by tumor location and morphology.International journal of surgery (London, England) · 2026Article
- Percutaneous Transthoracic Needle Biopsy May Increase Recurrence in Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matched Analysis.Annals of surgical oncology · 2026Article
- CT-Guided Transthoracic Core-Needle Biopsy of Pulmonary Nodules: Current Practices, Efficacy, and Safety Considerations.Journal of clinical medicine · 2024Review
- Effects of pre-operative biopsy on recurrence and survival in stage I lung adenocarcinoma patients in China.ERJ open research · 2023Article
- Radiological and clinical features of screening-detected pulmonary invasive mucinous adenocarcinoma.Interactive cardiovascular and thoracic surgery · 2022Article
- Computed Tomography-guided Lung Biopsy: A Review of Techniques for Reducing the Incidence of Complications.Interventional radiology (Higashimatsuyama-shi (Japan) · 2021Review
- Recurrence and disease-free survival outcomes after computed tomography-guided needle biopsy in stage IA non-small cell lung cancer patients in China: a propensity score matching analysis.Quantitative imaging in medicine and surgery · 2021Article
- CT-Guided Core Biopsy for Peripheral Sub-solid Pulmonary Nodules to Predict Predominant Histological and Aggressive Subtypes of Lung Adenocarcinoma.Annals of surgical oncology · 2020Article
- Analysis of indications for pulmonary peripheral lesions diagnosed using radial endobronchial ultrasound-guided transbronchial lung biopsy.Experimental and therapeutic medicine · 2020Article
- Is needle biopsy a risk factor of pleural recurrence after surgery for non-small cell lung cancer?Journal of thoracic disease · 2020Article
- Percutaneous transthoracic needle biopsy of the lung in the era of precision medicine.Journal of thoracic disease · 2019Article
- Recurrence risk after preoperative biopsy in patients with resected early-stage non-small-cell lung cancer: a retrospective study.Cancer management and research · 2018Article
- Efficacy of Percutaneous Direct Puncture Biopsy of Malignant Lung Tumors Contacting to the Pleura.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous transthoracic needle biopsies (PTNB) are widely used for the diagnosis of a peripheral pulmonary nodules, but the risk of pleural recurrence in lung cancer patients remains undetermined. Our meta-analysis aims to answer the question whether PTNB strategy increases the risk of recurrence. PubMed, EMBASE, The Cochrane Library, and China National Knowledge Infrastructure (CNKI) were searched from inception to January 9, 2016. A total of 1242 patients from 5 studies were included. The results showed that PTNB does not increase risk of total recurrence (Odds Ratio,0.78; 95% CI, 0.53 to 1.15) or pleural recurrence (Odds Ratio,1.58; 95% CI, 0.41 to 6.12) compared with non-PTNB strategies in early stage lung cancer patients. Subgroup analysis showed that PTNB was associated with increased pleural recurrence (Odds Ratio, 10.76; 95% CI, 2.92 to 39.70) in patients with sub-pleural lesions but not in patients without sub-pleural lesions (Odds Ratio, 0.96; 95% CI, 0.24 to 3.89). In conclusion, PTNB should not be recommended in lung cancer patients with sub-pleural lesions. However, PTNB is recommendable to use in other patients without sub-pleural lesions to whom pathological diagnosis is necessary, especially in patients with relevant comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.